Clinical Trials Browser

Completed × Brentuximab Vedotin × Dermatologic × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT02616965 2025-04-04

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Phase 1 Completed

16 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT03302728 2022-05-19

EpiBrentlen

Phase 1 Completed

6 enrolled

DermatologicLymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT01578499 2021-01-05

ALCANZA

Phase 3 Completed

131 enrolled 24 charts

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT01396070 2017-04-05

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

Phase 2 Completed

36 enrolled 13 charts

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00099255 2014-12-18

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Phase 2 Completed

40 enrolled

DermatologicLymphoidSarcoma

Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

NCT00051597 2011-10-12

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Phase 1/2 Completed

70 enrolled

DermatologicLymphoidSarcoma

Hodgkin Disease, Sarcoma, Kaposi, Lymphoma, B-Cell, Lymphoma, T-Cell, Cutaneous, Dendritic Cell Sarcoma, Interdigitating

Clinical Trials

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

EpiBrentlen

ALCANZA

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies